Genomic Testing Market Set For Strong Growth Through 2035, Fueled By Precision Medicine, Lower Sequencing Costs And Expanding Clinical Applications

(MENAFN- GlobeNewsWire - Nasdaq) NGS, personalized medicine and early cancer detection are driving adoption, creating opportunities in liquid biopsy, precision oncology, drug development and recurring consumables.

Dublin, Sept. 16, 2026 (GLOBE NEWSWIRE) -- "Genomic Testing Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering.

Genomic Testing Market to Reach USD 41.34 Billion by 2035 as Precision Medicine Adoption Accelerates

The global genomic testing market is experiencing substantial growth as genetic insights become increasingly important to healthcare delivery, biomedical research and pharmaceutical development. Valued at approximately USD 16.62 billion in 2025, the market is projected to reach USD 41.34 billion by 2035, expanding at a compound annual growth rate of 9.54% from 2026 to 2035.

Advances in next-generation sequencing are supporting faster, more accurate and cost-efficient genomic analysis. At the same time, the expanding use of personalized medicine is positioning genomic testing as an essential resource for disease diagnosis, treatment selection and clinical decision-making. Demand is particularly strong in oncology, where genomic profiling supports the identification of mutations, biomarkers and treatment-relevant genetic signatures.

Competitive Landscape and Market Developments

The genomic testing market remains highly competitive, with participants pursuing strategic partnerships, mergers, clinical validation programs and platform innovation. Illumina continues to lead the high-throughput short-read sequencing segment through its established platform portfolio, operational scale and broad clinical adoption.

Oxford Nanopore Technologies and PacBio have strengthened their positions in long-read sequencing, particularly for applications involving complex genomic regions. Competition is also intensifying among oncology genomic testing service providers. Natera and Exact Sciences continue to expand testing volumes, clinical evidence and commercial reach. Natera's reported 53% revenue growth in the fourth quarter of 2024 demonstrates the commercial potential of oncology-focused genomic testing.

Genomic Testing Market Growth Drivers

The rising global prevalence of chronic diseases, especially cancer, is a major driver of market expansion. According to 2024 updates from the World Health Organization, approximately 20 million new cancer cases are diagnosed worldwide each year. Global cancer incidence is projected to increase by 77% by 2050, creating greater demand for advanced diagnostic and treatment-selection technologies.

Genomic profiling is becoming increasingly integrated into oncology workflows, helping healthcare professionals stratify patients, evaluate therapeutic response and identify actionable mutations. As healthcare systems place greater emphasis on precision therapies and outcome-based care, genomic testing is progressing from a specialized service toward routine clinical use.

Next-generation sequencing accounts for a growing share of genomic testing demand across precision oncology, liquid biopsy, cancer gene therapy and measurable residual disease testing. Declining per-sample sequencing costs, expanding clinical evidence and increasing regulatory acceptance are expected to support wider adoption across global healthcare systems.

Market Challenges

Despite favorable growth prospects, the cost of genomic testing remains a significant barrier to widespread adoption. Sequencing instruments, proprietary reagents, bioinformatics infrastructure and specialized personnel require substantial investment. These expenses are especially restrictive in low- and middle-income markets, where limited laboratory capacity and healthcare funding can delay access.

Technology improvements are increasing efficiency, but equitable access remains a structural challenge. Market participants are therefore focusing on workflow automation, scalable testing models, decentralized sample collection and more efficient data analysis to improve affordability and availability.

Genomic Testing Market Segmentation

By offering, reagents and consumables lead the market with a 46.7% share. Recurring demand from installed sequencing systems provides manufacturers with sustained revenue from proprietary consumables and laboratory supplies.

By testing type, sequencing solutions, led by next-generation sequencing, account for 66.73% of the market. Growth is supported by the transition of sequencing from research-focused applications to routine clinical diagnostics, including liquid biopsy and measurable residual disease testing.

Drug discovery and development represents more than 46% of market revenue by application. Pharmaceutical and biotechnology companies use genomic testing for target validation, patient stratification, biomarker development and clinical trial optimization. Within the reported technology segmentation, stem cell therapy holds a 42.4% share, supported by genomic validation requirements in cell and gene therapy development and manufacturing.

Key Market Segments

• By offering: Systems and software; reagents and consumables; services; direct-to-consumer genomic testing services; and genomic data sales.
• By testing type: Sequencing solutions and microarray solutions.
• By technology: Proteomics, pharmacogenomics, stem cell therapy and cloning.
• By indication: Cancer, asthma, diabetes, heart disease and other indications.
• By application: Drug discovery and development, disease diagnosis, agricultural production and other applications.
• By end user: Hospitals and clinics; research centers and academic institutions; pharmaceutical and biotechnology companies; and other end users.
• By region: North America, Europe, Asia Pacific, the Middle East and Africa, and South America.

Regional Market Outlook

North America leads the global genomic testing market with approximately 35% of total revenue. The region benefits from favorable reimbursement policies, high healthcare expenditure, established sequencing infrastructure and strong institutional support for genomic research.

The United States remains central to regional growth, supported by government-backed programs including the National Institutes of Health's All of Us Research Program. By February 2025, the program had released genomic and health data from 633,000 participants, supporting research translation and the clinical integration of genomic insights. These advantages are expected to reinforce North America's market leadership.

Leading Genomic Testing Market Participants

• Agilent Technologies, Inc.
• BGI Group
• Bio-Rad Laboratories
• Danaher Corporation
• Eurofins Genomics
• F. Hoffmann-La Roche
• Illumina, Inc.
• QIAGEN
• Singular Genomics Systems, Inc.
• Thermo Fisher Scientific, Inc.
• Other prominent market participants

Continued innovation in sequencing platforms, oncology diagnostics, bioinformatics and precision medicine is expected to sustain genomic testing market growth through 2035. Companies that combine scalable technology, strong clinical evidence and cost-efficient testing models will be well positioned to capture emerging opportunities across healthcare, pharmaceutical research and biotechnology.

Key Attributes:

Report Attribute	Details
No. of Pages	372
Forecast Period	2025 - 2035
Estimated Market Value (USD) in 2025	$16.62 Billion
Forecasted Market Value (USD) by 2035	$41.34 Billion
Compound Annual Growth Rate	9.5%
Regions Covered	Global

Key Topics Covered:
Chapter 1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
Chapter 2. Research Methodology
2.1. Qualitative Research
2.1.1. Primary & Secondary Sources
2.2. Quantitative Research
2.2.1. Primary & Secondary Sources
2.3. Breakdown of Primary Research Respondents, By Region
2.4. Assumption for the Study
2.5. Market Size Estimation
2.6. Data Triangulation
Chapter 3. Executive Summary: Global Genomic Testing Market
Executive Summary: Global Genomic Testing Market
Chapter 4. Global Genomic Testing Market Overview
4.1. Industry Value Chain Analysis
4.1.1. Raw Material Supplier
4.1.2. Manufacturers
4.1.3. Distributors
4.1.4. End User
4.2. Industry Outlook
4.2.1. Genomic Data Analysis
4.2.2. Requisite infrastructure and organization for the entering
4.2.3. Regulatory Landscape W.R.T Region
4.2.3.1. North America Regulations/Laws
4.2.3.2. Europe Regulations/Laws
4.2.3.3. Asia Pacific Regulations/Laws
4.2.3.4. South America Regulations/Laws
4.2.3.5. Middle East & Africa Regulations/Laws
4.3. PESTLE Analysis
4.4. Porter's Five Forces Analysis
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Power of Buyers
4.4.3. Threat of Substitutes
4.4.4. Threat of New Entrants
4.4.5. Degree of Competition
4.5. Market Dynamics and Trends
4.5.1. Growth Drivers
4.5.2. Restraints
4.5.3. Challenges
4.5.4. Key Trends
4.6. COVID-19 Impact Assessment on Market Growth Trend
4.7. Market Growth and Outlook
4.7.1. Market Revenue Estimates and Forecast (US$ Bn), 2020 - 2035
4.7.2. Price Trend Analysis
4.8. Competition Dashboard
4.8.1. Market Concentration Rate
4.8.2. Company Market Share Analysis (Value %), 2025
4.8.3. Competitor Mapping
Chapter 5. Global Genomic Testing Market Analysis, By Offering
5.1. Key Insights
5.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
5.2.1. System and Software
5.2.2. Reagents & Consumables
5.2.3. Services
5.2.3.1. DTC Genomic Testing Service
5.2.3.2. Sale of genomic data
Chapter 6. Global Genomic Testing Market Analysis, By Testing Type
6.1. Key Insights
6.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
6.2.1. Sequencing Solution
6.2.1.1. DNA Sequencing
6.2.1.2. RNA Sequencing
6.2.1.3. Methylation Sequencing
6.2.1.4. NGS Library Preparation
6.2.1.5. Sequencing Data Analysis
6.2.1.6. Others
6.2.2. Microarray Solution
6.2.2.1. Human Genotyping with Arrays
6.2.2.2. Non-Human Genotyping with Arrays
6.2.2.3. Methylation Array Analysis
6.2.2.4. Microarray Data Analysis
6.2.2.5. Others
Chapter 7. Global Genomic Testing Market Analysis, By Technology
7.1. Key Insights
7.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
7.2.1. Proteomics
7.2.2. Pharmacogenomics
7.2.3. Stem Cell Therapy
7.2.4. Cloning
Chapter 8. Global Genomic Testing Market Analysis, By Indication
8.1. Key Insights
8.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
8.2.1. Cancer
8.2.2. Asthma
8.2.3. Diabetes
8.2.4. Hearth Diseases
8.2.5. Other Indication
Chapter 9. Global Genomic Testing Market Analysis, By Application
9.1. Key Insights
9.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
9.2.1. Drug Discovery & Development
9.2.2. Disease Diagnosis
9.2.3. Agricultural Production
9.2.4. Others
Chapter 10. Global Genomic Testing Market Analysis, By End User
10.1. Key Insights
10.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
10.2.1. Hospitals & Clinics
10.2.2. Research Centers & Academic Institutions
10.2.3. Pharmaceutical & Biotechnology Companies
10.2.4. Others
Chapter 11. Global Genomic Testing Market, Cross Analysis
1.1. Key Insights
11.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
11.2.1. By Offering, By Application, By End User
Chapter 12. Global Genomic Testing Market Analysis, By Region
12.1. Key Insights
12.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
12.2.1. North America
12.2.1.1. The U.S.
12.2.1.2. Canada
12.2.1.3. Mexico
12.2.2. Europe
12.2.2.1. Western Europe
12.2.2.1.1. The UK
12.2.2.1.2. Germany
12.2.2.1.3. France
12.2.2.1.4. Italy
12.2.2.1.5. Spain
12.2.2.1.6. Rest of Western Europe
12.2.2.2. Eastern Europe
12.2.2.2.1. Poland
12.2.2.2.2. Russia
12.2.2.2.3. Rest of Eastern Europe
12.2.3. Asia Pacific
12.2.3.1. China
12.2.3.2. India
12.2.3.3. Japan
12.2.3.4. South Korea
12.2.3.5. Australia & New Zealand
12.2.3.6. ASEAN
12.2.3.7. Rest of Asia Pacific
12.2.4. Middle East & Africa
12.2.4.1. UAE
12.2.4.2. Saudi Arabia
12.2.4.3. South Africa
12.2.4.4. Rest of MEA
12.2.5. South America
12.2.5.1. Argentina
12.2.5.2. Brazil
12.2.5.3. Rest of South America
Chapter 13. North America Genomic Testing Market Analysis
13.1. Key Insights
13.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
13.2.1. By Offering
13.2.2. By Testing Type
13.2.3. By Technology
13.2.4. By Indication
13.2.5. By Application
13.2.6. By End User
13.2.7. Cross Analysis
13.2.8. By Country
Chapter 14. Europe Genomic Testing Market Analysis
14.1. Key Insights
14.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
14.2.1. By Offering
14.2.2. By Testing Type
14.2.3. By Technology
14.2.4. By Indication
14.2.5. By Application
14.2.6. By End User
14.2.7. Cross Analysis
14.2.8. By Country
Chapter 15. Asia Pacific Genomic Testing Market Analysis
15.1. Key Insights
15.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
15.2.1. By Offering
15.2.2. By Testing Type
15.2.3. By Technology
15.2.4. By Indication
15.2.5. By Application
15.2.6. By End User
15.2.7. Cross Analysis
15.2.8. By Country
Chapter 16. Malaysia Genomic Testing Market Analysis
16.1. Key Insights
16.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
16.2.1. By Offering
16.2.2. By Testing Type
16.2.3. By Technology
16.2.4. By Indication
16.2.5. By Application
16.2.6. By End User
16.2.7. Cross Analysis
Chapter 17. Thailand Genomic Testing Market Analysis
17.1. Key Insights
17.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
17.2.1. By Offering
17.2.2. By Testing Type
17.2.4. By Indication
17.2.5. By Application
17.2.6. By End User
17.2.7. Cross Analysis
Chapter 18. Middle East and Africa Genomic Testing Market Analysis
18.1. Key Insights
18.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
18.2.1. By Offering
18.2.2. By Testing Type
18.2.3. By Technology
18.2.4. By Indication
18.2.5. By Application
18.2.6. By End User
18.2.7. Cross Analysis
18.2.8. By Country
Chapter 19. UAE Genomic Testing Market Analysis
19.1. Key Insights
19.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
19.2.1. By Offering
19.2.2. By Testing Type
19.2.3. By Technology
19.2.4. By Indication
19.2.5. By Application
19.2.6. By End User
19.2.7. Cross Analysis
Chapter 20. South America Genomic Testing Market Analysis
20.1. Key Insights
20.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
20.2.1. By Offering
20.2.2. By Testing Type
20.2.3. By Technology
20.2.4. By Indication
20.2.5. By Application
20.2.6. By End User
20.2.7. Cross Analysis
20.2.8. By Country
Chapter 21. Brazil Genomic Testing Market Analysis
21.1. Key Insights
21.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
21.2.1. By Offering
21.2.2. By Testing Type
21.2.3. By Technology
21.2.4. By Indication
21.2.5. By Application
21.2.6. By End User
21.2.7. Cross Analysis
Chapter 22. Company Profiles (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)
22.1. Agilent Technologies, Inc.
22.2. BGI Group
22.3. Bio-Rad Laboratories
22.4. Danaher Corporation
22.5. Eurofins Genomics
22.6. F. Hoffmann-La Roche
22.7. Illumina, Inc.
22.8. QIAGEN
22.9. Singular Genomics Systems, Inc.
22.10. Thermo Fisher Scientific, Inc.
22.11. Other Prominent players
A selection of companies mentioned in this report includes, but is not limited to:

• Agilent Technologies, Inc.
• BGI Group
• Bio-Rad Laboratories
• Danaher Corporation
• Eurofins Genomics
• F. Hoffmann-La Roche
• Illumina, Inc.
• QIAGEN
• Singular Genomics Systems, Inc.
• Thermo Fisher Scientific, Inc.

For more information about this report visit

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN16092026004107003653ID1111672480